| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g | |||
| 50g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
β-tubulin (no IC50, Ki, EC50, or DC50 values provided in this study).[1]
|
|---|---|
| ln Vitro |
Flubendazole results in morphological changes included contraction of the soma region, formation of blebs on the tegument, rostellar disorganization, loss of hooks and destruction of microtriches in Echinococcus granulosus. Flubendazole have a bicyclic ring system in which a benzene has been fused to the -4 and -5 positions of the heterocycle (imidazole). Flubendazole and Albendazole shows similar potency in affecting rat embryonic development in vitro, inducing retardation of growth and dysmorphogenic effects at concentrations ≥0.5 μg/mL.
Flubendazole at concentrations of 10, 5 and 1 μg/ml provoked a protoscolicidal effect against Echinococcus granulosus protoscoleces in vitro, reducing vitality to 35.6±0.7% after 18 days of incubation. After 25 days of incubation, the percentage of vital protoscoleces was 13.9±5.9%. After 30 days, mortality was 100% at concentrations of 10 and 1 μg/ml, and only 0.7±0.7% vital protoscoleces were observed at 5 μg/ml. The primary site of damage was the tegument of the parasite. At 3 days post-incubation (p.i.), numerous blebs on the tegument were observed. At 6 days p.i., soma region contraction and numerous blebs on the scolex tegument were seen; microtriches remained unaltered. At 12 days p.i., rostellar disorganization, loss of hooks, shedding of microtriches, and digitiform tegumental extensions on the soma region were observed; large vacuoles appeared in the distal cytoplasm. At 18 days p.i., loss of morphology, loss of hooks, altered sucker region with blebs, and no detectable microtriches were evident; soma region contracted with markedly altered tegument. At 25 days p.i., complete loss of morphology, rostellar disorganization, complete shedding of microtriches, severely affected internal tissue with increased lipid droplets, and vitality approximately 13.9±5.9%. Flubendazole killed protoscoleces considerably faster than albendazole (ABZ) or albendazole sulphoxide (ABZSO); after 25 days exposure to Flubendazole, vitality was ~13.9±5.9% compared to 50% after 24 days with ABZ or ABZSO.[1] Time of appearance of tissue damage indicators: contraction of soma region at 6 days p.i.; formation of blebs on tegument at 6 days p.i.; rostellar disorganization at 12 days p.i.; complete shedding of microtriches at 18 days p.i.[1] |
| ln Vivo |
Flubendazole (6.32 mg/kg/day) initially induces an arrest of embryonic development followed by a generalized cell death that leads to 100% embryolethality by gestation day (GD) 12.5. Flubendazole (3.46 mg/kg/day) markedly reduces embryonic development by GD 12.5 without causing cell death. Flubendazole in olive oil causes a statistically significant increase in embryolethality at doses of 7.83 mg/kg per day and higher, with complete resorption in all dams at 31.33 mg/kg per day in rats. Flubendazole treatment causes a slight increase of metyrapone and daunorubicin activities in hepatic as well as intestinal cytosol in birds. Flubendazole treatment leads to statistically significant inhibition of intestinal GST activity. Flubendazole treatment leads to slight but significant inhibition (decrease to 69%) of 7-ethoxyresorufin activity in hepatic microsomes.
|
| Cell Assay |
Protoscoleces of Echinococcus granulosus were collected aseptically from liver and lung hydatid cysts of infected cattle. Viability was assessed by muscular movements (evaluated under light microscope), morphological perfectness of the whole body determined using scanning electron microscopy (SEM) and transmission electron microscopy (TEM), motility of flame cells, and by the methylene blue exclusion test. Viable and free protoscoleces (1,500 per Leighton tube) were cultured in medium 199 spiked with 100 IU penicillin, 100 μg/ml streptomycin and 4 mg/ml glucose. Cultures were performed in 10 ml of incubation medium at 37°C without changes of medium. Flubendazole was dissolved in dimethyl sulphoxide (DMSO) at a drug concentration of 10 mg/ml and added to the medium resulting in final concentrations of 10, 5 and 1 μg/ml. Protoscoleces incubated with culture medium alone and with culture medium containing DMSO were used as controls. Culture tubes were followed microscopically every day. Samples of protoscoleces (approximately 70-90 protoscoleces in 0.5 ml of incubation medium) from each dosing group and controls were taken every 5-6 days for up to 46 (control group) or 35 (Flubendazole group) days. Vitality of protoscoleces was assessed using the methylene blue exclusion technique. Additionally, ultrastructure studies with SEM and TEM were performed. For SEM, samples were fixed with 3% glutaraldehyde in sodium cacodylate buffer for 24 h at 4°C, washed in cacodylate buffer, dehydrated in increasing concentrations of ethanol (50-100%), immersed in hexamethyldisilazane for 5 min, 1 h and then overnight, sputter-coated with gold (100 Å thick), and inspected on a scanning electron microscope operating at 15 kV. For TEM, samples were post-fixed in 2% OsO4 in cacodylate buffer, washed in water, dehydrated in a graded acetone series, embedded in Spurr's resin, polymerized at 70°C overnight, sections 700 Å thick were cut, stained with uranyl acetate saturated solution (45 min) and lead citrate (20 min), and examined with a transmission electron microscope at 80 kV.[1]
|
| Animal Protocol |
6.32, 7.83, 31.33 mg/kg/day Birds
|
| References |
Parasitol Res.2006 Mar;98(4):317-23.
|
| Additional Infomation |
Flubendazole belongs to the mebendazole class of drugs, with its benzoyl group replaced by a p-fluorobenzoyl group. It is a broad-spectrum anthelmintic, particularly used in veterinary medicine to treat nematode infections. It is both an anti-nematode and a teratogen. It belongs to the benzimidazole, carbamate, organofluorine, and aromatic ketone classes of compounds. Flubendazole is an anthelmintic used to treat human helminth infections. In Europe, it is available without a prescription.
Flubendazole (FLBZ) is a benzimidazole methylcarbamate anthelmintic. Benzimidazole anthelmintics exert their action by binding to β-tubulin, thereby inhibiting the polymerization of microtubules, which induces blockage of glucose absorption, glycogen depletion, degenerative alterations in the endoplasmic reticulum and mitochondria of the germinal layer, and an increase in lysosomes with consequent cellular autolysis. Mebendazole (MBZ) and albendazole (ABZ) have been used for treatment of human hydatid disease. Flubendazole has been used to treat cystic echinococcosis in humans but low in vivo efficacy has been reported. This work describes for the first time the protoscolicidal effect of Flubendazole in vitro on cultured Echinococcus granulosus. The authors concluded that further in vitro (at lower concentrations) and in vivo experiments are required to fully evaluate the potential of Flubendazole as a useful anthelmintic for treatment of CE.[1] |
| Molecular Formula |
C16H12FN3O3
|
|
|---|---|---|
| Molecular Weight |
313.28
|
|
| Exact Mass |
313.086
|
|
| CAS # |
31430-15-6
|
|
| Related CAS # |
Flubendazole-d3;1173021-08-3
|
|
| PubChem CID |
35802
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Melting Point |
290°C
|
|
| Index of Refraction |
1.685
|
|
| LogP |
3.05
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
454
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(OC)NC1=NC2=CC=C(C(C3=CC=C(F)C=C3)=O)C=C2N1
|
|
| InChi Key |
CPEUVMUXAHMANV-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C16H12FN3O3/c1-23-16(22)20-15-18-12-7-4-10(8-13(12)19-15)14(21)9-2-5-11(17)6-3-9/h2-8H,1H3,(H2,18,19,20,22)
|
|
| Chemical Name |
methyl (5-(4-fluorobenzoyl)-1H-benzo[d]imidazol-2-yl)carbamate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1920 mL | 15.9602 mL | 31.9203 mL | |
| 5 mM | 0.6384 mL | 3.1920 mL | 6.3841 mL | |
| 10 mM | 0.3192 mL | 1.5960 mL | 3.1920 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.